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Mutations in N-RAS and B-RAF, which commonly occur in
melanomas, result in constitutive activation of the mitogen-ac-
tivated protein kinase (MAPK)/extracellular signal-regulated
protein kinase (ERK) signaling.Active ERK increases expression
and activity of the c-Jun transcription factor, linking ERK and
JunN-terminal kinase (JNK) cascades. Here, we show that c-Jun
regulates transcription of phosphoinositide-dependent kinase 1
(PDK1) with a concomitant impact on Akt and protein kinase C
(PKC) activity and related substrates. Inhibition of c-Jun
reduces PDK1 expression and attenuates Akt and PKC activity,
which can be restored by exogenous PDK1. c-Jun regulation of
PDK1 inmelanoma contributes to growth rate and the ability to
form tumors inmice. Correspondingly, increased levels of c-Jun
inmelanoma cell lines coincidewith up-regulation of PDK1 and
phosphorylation of PKC and Akt. The identification of c-Jun as
a transcriptional regulator of PDK1 expression highlights key
mechanisms underlying c-Jun oncogenic activity, and provides
new insight into the nature of up-regulated Akt and PKC in
melanoma.
c-Jun is a primary component of the AP-1 transcription
complex regulated by the JNK4 signaling pathway, and con-
tributes to cell proliferation, cell death, and inflammation in
response to a plethora of extracellular stimuli (1). Mounting
evidence indicates that cellular Jun is involved in human
cancer. It is frequently overexpressed, and the full oncogenic
properties of some cancer cells might require elevated Jun
function. No activating Jun mutations have been found in
human cancers, and there have been no reports of C-JUN
amplification or recurring chromosomal translocations that
involve C-JUN. Instead, c-Jun can be constitutively up-reg-
ulated by activation of upstream kinases. We recently found
that constitutively active ERK, which is commonly found in
melanoma due to activating mutations in B-RAF or N-RAS
(2, 3), increases C-JUN transcription and stability via cAMP
response element-binding activation and glycogen synthase
kinase 3 (GSK3) inactivation, respectively (4). Consistent
with its regulation by ERK, c-Jun phosphorylation is
required for Ras-induced transformation of fibroblasts in
vitro and Ras-induced skin tumorigenesis in vivo (5). Along
these lines, c-Jun has been shown to be oncogenic in several
tumor types, including human sarcomas (6), breast cancer
(7), and lung cancer (8). Moreover, a genetic mouse model
revealed c-Jun oncogenic activity in liver tumors, in part
through antagonizing the tumor suppressor protein p53 (9).
Studies from our laboratory indicate an important role of
c-Jun together with its heterodimeric partner activating
transcription factor 2 in acquisition of resistance to apopto-
sis by melanoma cells (10). This observation, combined with
up-regulation of c-Jun in melanoma due to re-wired ERK
signaling (4), underscores its role in melanoma.
Although several c-Jun target genes have been identified, the
mechanism by which c-Jun affects tumorigenesis is not com-
pletely understood (11). In the present workwe show that c-Jun
regulates cell growth and tumorigenesis by regulating phospho-
inositide-dependent kinase 1 (PDK1) and their targets. PDK1 is
a Ser/Thr kinase required for activation of protein kinases in
the AGC kinase superfamily that play important roles in cancer
progression, such as protein kinase B (also known as Akt), pro-
tein kinase C (PKC), and S6K (12, 13). To be active, these
kinases require phosphorylation at both the activation loop and
the hydrophobic domain (e.g. Thr308 and Ser473 for Akt1) by
PDK1 and mammalian target of rapamycin complex 2, respec-
tively (14, 15). Because PDK1 is activated upon autophosphor-
ylation, its kinase activity is thought to be regulated by pro-
tein-protein interaction, changes in subcellular localization,
orotherphosphorylation-independentmechanisms(16).c-Jun-
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dependent regulation of PDK1 and subsequent activation of
downstream substrates Akt and PKC in melanoma offers
important new insight into the mechanism underlying c-Jun
oncogenic activity.
EXPERIMENTAL PROCEDURES
Melanoma Samples and Cell Lines—Melanoma samples
were obtained from regional dermal metastases, nodal metas-
tases, or distant sites of metastases as described (4). Melanoma
lines were kindly provided by Dr. M. Herlyn. c-Jun mutant
fibroblasts were kindly provided by R. Wisdom. Cells were
transfected with calcium phosphate or by Lipofectamine PLUS
reagent (Invitrogen) following the manufacturer’s protocol.
Constructs—Constructs encoding glutathione S-transferase-
Jun-(1–89), MEKK, and FLAG-TAM67 were previously
described (10, 17). FLAG-TAM67 was cloned into pBABE-
Puro. TAM67 inhibits AP-1 activity by dimerizing with wild-
type AP-1 proteins to yield low activity dimers containing only
one transactivation domain. A plasmid encoding MEKK was
kindly provided by M. Karin. pBABE myr-Akt was provided by
Dr. P. Tsichlis. Plasmids encoding WT PDK1 and the A280V
mutantwere kindly provided byDr. Liu (18). cDNAs from these
plasmids were cloned into pBABE-Hygro. Viral particles were
obtained from supernatants of transfected human embryonic
kidney 293T cells.
RNA Interference—siCONTROL (scrambled) and PDK1-
specific SMARTpool reagents were used (Dharmacon). c-Jun-
specific siRNA oligonucleotide was obtained fromQiagen, and
Sp1-specific and Ets-1-specific siRNA oligonucleotides from
Ambion. c-Jun-specific shRNA clones were obtained from
Open Biosystems. Transfection of 50 nM duplexes into mela-
noma cells was performed using Lipofectamine 2000 or nucleo-
fection using Amaxa reagent V. Lentiviral shRNA clones pack-
aged in human embryonic kidney 293T cells were used for
corresponding infections. Protein extracts were obtained
48–60 h after transfection.
Antibodies and Immunoblotting—Antibodies and reagents
were purchased as follows: antibodies to JNK1, JNK2, P-c-Jun,
c-Jun, P-RSK2 (Ser227), GSK, SP1, and Ets-1 were from Santa
Cruz Biotechnologies. Antibodies to PDK1, P-Akt (Thr308),
P-Akt (Ser473), Akt, pan-P-PKC (activation loop site, Thr514 of
PKC), pan-P-PKC (hydrophobic site, Ser660 of PKCII), pan-
PKC, P-JNK (Thr183/Tyr185), P-Foxo3a, Foxo3a, P-GSK3 (S9),
RSK2, S6K1, proliferating cell nuclear antigen, and c-Jun
(L70B11) were from Cell Signaling. Because PKC autophos-
phorylation at the hydrophobic site in a given melanoma cell
line depends on the efficiency of activation loop phosphoryla-
tion by PDK1, we used the P-PKC (Ser660) antibody to monitor
activation loop phosphorylation. Antibodies to PRAS40 and
P-PRAS40 (Thr246) were from Invitrogen. Antibodies to
P-S6K1 (Thr229) were from Abcam. Antibodies against PKC
isoforms were from BD Biosciences. Antibodies to hemag-
glutinin and FLAGwere from Babco and Sigma, respectively.
Final concentrations of reagents were as follows: LY294002
(Calbiochem), 10 M; MG132 (Calbiochem), 10 M; actino-
mycin D (5 g/ml). Protein extract preparation andWestern
blot analysis were as described (4). -Actin or -tubulin
antibodies were used to monitor loading. Where multiple
bands are present (i.e. in PDK1 and c-Jun blots) the relevant
band (see Fig. 1, arrow) was confirmed by siRNA and/or by
using different antibodies.
Real Time PCR—Real Time PCRwas performed as described
(4). Specific primers used for PCR were as follows: PDK1 for-
ward, tgactgcaaagatggaaacg; PDK1 reverse, tgagaaggtccgagt-
tcttg. Human -actin served as an endogenous control. Reac-
tions were run in triplicate. The target mRNA concentration of
control cells, normalized to the level of -actin mRNA, was set
to 1.
Chromatin Immunoprecipitation—Chromatin immunopre-
cipitation was performed using the Magna-Chip (Upstate)
according to the manufacturer’s instructions. Cells were fixed
with 37% formaldehyde and sheared chromatin from Lu1205
melanoma cells was immunoprecipitated and subjected to
PCR. The following primers corresponding to the proximal
region of the PDK1 promoter were used: forward, cggcgcgacg-
gaagtcctgc; reverse, tcctcctccccgaagcggag. Antibodies against
Sp1, c-Fos, and c-Jun (sc-44 and sc-45) were from Santa Cruz
Biotechnologies. IgG control, anti-AcH3 antibody, and glycer-
aldehyde-3-phosphate dehydrogenase oligonucleotides were
provided by the kit. All antibodies were polyclonal.
Avidin-Biotin Complex DNA Binding Assay—Nuclear
extracts obtained by using NE-PER extraction reagents
(Thermo Scientific) were supplemented with 0.5% Nonidet
P-40 and incubated with 3 g of biotin-labeled box 3 oligo (5-
GGGCGACGGGGCGGGCGCAGGATG-3) in the presence
of poly-(dI-dC) (20 g/ml) for 2 h. Box 3 oligo-bound proteins
were captured using streptavidin-agarose (Invitrogen) (1 h
incubation), followed by extensive washes with washing buffer
(20mMHEPES, 150mMNaCl, 20% glycerol, 0.5mMEDTA, and
0.5%Nonidet P-40) and analysis using SDS-PAGE andWestern
blots.
Luciferase Assays—The PDK1 promoter was amplified from
genomic DNA from HeLa cells. Fragments of different lengths
from the PDK1 promoter were amplified using the GC-rich
PCR kit (Roche) and cloned into pGL2-basic vector using KpnI
and HindIII. Site-directed mutagenesis of AP-1 and Sp1 sites
were performed using the QuikChange II kit (Stratagene) fol-
lowing the manufacturer’s protocol. HeLa, MeWo, SW1, or
Lu1205 cells were transfected with reporter plasmid along with
control vector, c-Jun, or TAM67. Cell lysates were prepared
from cells after 24 or 48 h. Luciferase activity was normalized
with -galactosidase activity. Results are shown as the mean
(bar) S.D.
PDK1 and Akt Kinase Activity—PDK1 kinase activity was
measured in PDK1 immunoprecipitates obtained from 600 g
of protein extracts from Jun/ and Jun/ fibroblasts. PDK1
kinase activities were measured using the PDK1 Immunopre-
cipitation Kinase Assay Kit (Upstate). The activity of Akt was
measured in immunoprecipitates obtained from 600g of pro-
tein extracts by an Akt kinase assay using histone 2B as a sub-
strate as described by Chan et al. (19).
Xenograft Assay and Cell Growth in Culture—Formeasuring
in vitro growth, Lu1205, Lu1205 expressing TAM67, and
Lu1205 cells expressing both TAM67 and the PDK1 constitu-
tive active form (A280V)were plated (104 cells/well) at day 0. At
days 3, 5, 7, and 9, cells were trypsinized and counted. The
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mediumwas changed every 3 days. For the assessment of in vivo
tumor growth, the cells described above were trypsinized,
resuspended in phosphate-buffered saline, and injected subcu-
taneously (1.5 106) into 8-week-old female nude mice in the
lower left flank. For tumor growth of c-Jun knockdown cells,
Lu1205 and Lu1205 cells stably expressing PDK1(A280V) were
transduced with c-Jun shRNA lentiviral clones. After selection
using puromycin, each group of cells (5  105) was injected
subcutaneously into a group of 5 mice as described above.
Tumor size was measured every week.
RESULTS
c-Jun Regulates PDK1 Transcrip-
tion—We recently showed that ERK
activation of c-Jun contributes to
increased JNK activity, through
transcription of receptor for acti-
vated C kinase-1 (RACK1), a PKC
adaptor protein that enhances JNK
activity (17, 20). In pursuing these
studies we observed a decrease in
total and P-PKC levels in cells with
impaired c-Jun function (see
below). Because PKC phosphoryla-
tion within its activation loop by
PDK1 affect its stability and activity
(12, 21), we have explored the possi-
ble impact of c-Jun on PDK1 activ-
ity. Analysis of mouse fibroblasts
deficient in c-Jun (22) and mela-
noma cells in which c-Jun transcrip-
tional activities are effectively inhib-
ited by a dominant-negative c-Jun
construct (TAM67) or c-Jun siRNA
revealed a marked reduction of
PDK1protein levels (Fig. 1,A–C). In
line with diminished PDK1 expres-
sion, c-Jun-deficient fibroblasts also
exhibited reduced PDK1 kinase
activity (Fig. 1D). Consistent with
these findings, expression in human
embryonic kidney 293T cells of
constitutively active MEKK1
(MEKK1), which elicits strong
activation of JNK and c-Jun,
increased activation of c-Jun and
elevated PDK1 expression levels
(Fig. 1E). These data suggest that
c-Jun positively regulates PDK1
expression. To assess a possible role
of c-Jun in regulation of PDK1
mRNA, we performed real time
PCR. A marked inhibition of PDK1
transcription was observed in cells
in which c-Jun expression was
either absent or inhibited by
TAM67 (Fig. 1F), suggesting that
changes seen at the protein level
may be attributed to regulation of
PDK1 mRNA levels by c-Jun.
To determine whether c-Jun also affects PDK1 protein levels
by affecting its degradation, we monitored changes in PDK1
steady state levels in the presence of the proteasome inhibitor
MG132. PDK1 protein levels were slightly increased following
MG132 treatment (supplemental Fig. S1); however, we attrib-
ute this to increased PDK1mRNA levels (supplemental Fig. S2)
resulting from MG132-induced c-Jun stabilization. Similarly,
neither PDK1 mRNA nor protein levels increased following
FIGURE 1. c-Jun regulates PDK1 transcription. A, c-Jun regulates PDK1 expression. Protein extracts (40 g)
from SW1 cells stably transfected with FLAG-TAM67 and control SW1 cells were blotted with PDK1 and FLAG
antibodies. B, PDK1 levels are regulated by c-Jun expression. Protein extracts (40g) from c-Jun/ fibroblasts
and c-Jun/ fibroblasts were blotted with the indicated antibodies. C, c-Jun siRNA decreases PDK1 protein
levels in melanoma. Protein extracts (40 g) from Lu1205 cells transfected with scrambled (sc) oligonucleo-
tides or a siRNA specific for c-Jun were analyzed by Western blots using the indicated antibodies. D, PDK1
activity is reduced in c-Jun/ fibroblasts. Protein extracts from c-Jun/ or c-Jun/ fibroblasts were immu-
noprecipitated with PDK1 antibody, and PDK1 kinase activity was measured by an in vitro kinase assay as
indicated under “Experimental Procedures.” Results shown are mean  S.D. of three independent experi-
ments. E, activation of the JNK/c-Jun pathway increases PDK1 expression. Human embryonic kidney 293T cells
were transfected with 0.2 g of MEKK1 or empty pEF plasmid. Protein extracts were obtained 48 h post-
transfection and blottedwith the indicated antibodies. The arrow indicates bands corresponding to PDK1 and
MEKK1. F, inhibition of c-Jundecreases PDK1mRNA levels. Relative levels of PDK1mRNAwere determinedby
real time PCR in c-Jun/ and control fibroblasts and in control SW1 and SW1-TAM67 cells. Results shown are
mean  S.D. of the respective relative concentrations. A representative experiment (of three performed) is
shown.
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MG132 treatment in TAM67-expressing cells (supplemental
Figs. S2 and S3). These results suggest that PDK1 degradation is
not altered by c-Jun and that changes in PDK1 levels observed
in c-Jun-deficient cells are due to decreased PDK1 mRNA lev-
els. Because c-Jun did not affect PDK1 mRNA stability either
(supplemental Fig. S4), we assessed whether c-Jun regulates
PDK1 mRNA levels by increasing its transcription. Consensus
AP-1 sites were identified at position924 and between900
and 300 of the PDK1 promoter (supplemental Fig. S5).
Although transfection of c-Jun increased the luciferase activity
driven by the 971 to 82 fragment of PDK1 promoter (sup-
plemental Figs. S6–S9) mutating or deleting the AP-1 site did
not affect the reporter activity (supplemental Fig. S6–S8). Sim-
ilarly, the decrease on reporter activity induced by TAM67 per-
sisted after mutation or deletions were performed on the PDK1
promoter (supplemental Fig. S6–S8). Intriguingly, 3 GC-rich
boxes between45 and82 were found to mediate c-Jun-de-
pendent trans-activation of the PDK1 promoter (supplemental
Figs. S8 and S9 and Fig. 2, A–C). These boxes contain 5 Sp1
(5-GGGCGG-3) sites that are conserved between human and
mouse, but not AP-1 response elements (Fig. 2A). Mutations
that alter Sp1 box 1, together with deletion of box 2 (45/82
M12) reduced overall reporter activity (Fig. 2B), but did not
abolish responsiveness to c-Jun expression (45/82WT, Fig.
2B). On the other hand, mutations within box 3 (45/82M3)
barely affected basal transcription but attenuated (8-fold)
c-Jun-mediated transcription (Fig. 2B). Consistent with these
observations, c-Jun siRNA reduced transcription driven by the
45/82 M12 fragment but not by the box 3-mutated con-
struct (Fig. 2C). In line with this data, c-Junmediated transcrip-
tion was abrogated when box 3 mutations were introduced in a
large fragment (875/82) of the PDK1 promoter (Fig. 2D).
FIGURE 2. c-Jun enhances PDK1 transactivation through a Sp1 site. A, structure of the proximal region of the human PDK1 promoter. The region from45
to82 contains 3boxeshighly conservedbetweenhumanandmouse (box1 from14 to2, box2 from4 to15, andbox3 from26 to37of thehuman
promoter). In addition to the WT sequence, fragments containing mutations in box 1 and deletion of box 2 as well as mutation in box 3 were cloned in pGL2
vector for reporter assays. B, c-Jun enhances PDK1 transactivation through a Sp1 site in box 3. Reporter plasmids described in panel A were transfected into
MeWo cells togetherwith empty vector or pcDNA-c-Jun. Results are shown as themean S.D.C, c-Jun siRNAno longer affect transcription driven by amutant
Sp1 site on box 3. Reporter plasmids described in panel Awere transfected into Lu1205 cells togetherwith scramble (sc) or c-Jun siRNA.D, mutation on the Sp1
site on box 3 abrogates responsiveness to c-Jun of the PDK1 promoter. A large region of the PDK1 promoter (875 to82) was subjected to mutagenesis of
the Sp1 site on box 3 and the activity of both theWT andmutant promoter was assessed using reporter assays. Luciferase data are shown as themean S.D.
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These results suggest that c-Jun enhances PDK1 transcription
through Sp1 sites located in box 3. Consistentwith our findings,
Sp1was shown capable of recruiting c-Jun for transactivation of
a number of genes including 12(S)-lipoxygenase, keratin 16,
neuronal nicotinic acetylcholine receptor4, and p21WAF1/CIP1
(23–26). Further support for the role of c-Jun in the regulation of
PDK1 transcription comes from immunoprecipitation experi-
ments and chromatin immunoprecipitation analysis. Sp1 and
c-Jun do interact in melanoma cells (Fig. 3A) and chromatin
immunoprecipitationofSp1, c-Jun,orc-Fosenabledamplification
of PDK1 promoter sequences bearing the Sp1 box 3 sequences
(Fig. 3B), demonstrating in vivo binding of these transcription fac-
tors to a 130-bp fragment from the PDK1 promoter containing
Sp1boxes1 to3.As expected, binding
of c-Jun to the promoter was reduced
in cells transfected with c-Jun siRNA
(Fig. 3, C and D). To further demon-
strate binding of c-Jun to box 3 we
performed gel shift assays. Binding of
c-Jun to the 21-bp box 3 bearing oligo
was inhibited by a competitor oligo
but not by a oligo with amutated box
3 sequence (data not shown). Fur-
thermore, we determined c-Jun bind-
ing to box 3 by a pull-down experi-
ment using a biotinylated oligo. As
shown in Fig. 3E, the box 3 oligo effi-
ciently pulled down both c-Jun and
Sp1 as revealed by Western blot. To
test whether Sp1 is a prerequisite for
c-Jun binding to the box 3 sequence,
we performed an oligo pull-down
assay using protein extracts from
Sp1 knockdown cells. In line with
previous observations, the binding
of c-Jun to the box 3 sequence was
significantly reduced (Fig. 3F).
However, despite efficient inhibi-
tion of Sp1 expression, residual
binding of c-Jun to box 3 oligonu-
cleotide was observed. Further-
more, inhibition of Sp1 expression
did not decrease PDK1 expression
(data not shown), indicating that
either other members of the Sp1
family, or additional transcription
factors mediate c-Jun regulation of
PDK1 transcription. Among possi-
ble transcription factors that can
bind to GC-rich regions of the
PDK1 promoter and have been
associated with AP-1, we identified
the Ets-1 binding sequence in the 3
end of the box 3 oligonucleotide
(Fig. 2A, double underlined se-
quence, and Refs. 27–29). To test
the possible role of Ets-1 in PDK1
expression we have assessed the lev-
els of transcripts upon inhibition of Ets1 expression. Reduced
expression of Ets-1 by RNA interference resulted in marked
inhibition of PDK1 expression without changes in Sp1 and
c-Jun expression (Fig. 3G). Furthermore, Ets-1 expression was
affected by c-Jun, consistent with a previous report on regula-
tion of Ets-1 expression by AP-1 (see Ref. 30 and Fig. 3H). Alto-
gether, these results indicate that c-Jun regulates the transcrip-
tion of PDK1 through cooperation with Sp1 and Ets-1 and their
corresponding response elements on the PDK1 promoter.
Because c-Jun also controls Ets-1 transcription, regulation of
PDK1 involves both direct and indirect function of c-Jun.
c-Jun Regulation of PDK1 Modulates Akt Activity—Because
the PDK1 level is a major determinant in its activity given its
FIGURE 3. A, c-Jun enhances PDK1 transactivation through Sp1 and Ets. c-Jun interacts with Sp1 in melanoma
cells. Nuclear extracts fromMeWo cells andMeWo cells stably transfected with FLAG-c-Jun were immunopre-
cipitated (IP) with FLAG antibodies and blotted (IB) with the indicated antibodies. B, chromatin immunopre-
cipitation assay. The products of PDK1- and glyceraldehyde-3-phosphate dehydrogenase-specific PCR ampli-
fication on IPmaterial from Lu1205 cells are shown. c-Jun antibodies sc-44 and sc-45were used. C, c-Jun siRNA
decrease binding of c-Jun to the PDK1promoter. A chromatin immunoprecipitation assaywas performedwith
extracts fromLu1205cells transfectedwith scramble (sc) or c-Jun siRNA.D, protein extracts fromcells described
in panel C were analyzed by Western blot using the indicated antibodies. E and F, c-Jun binds to the box 3
region from the PDK1 promoter. Protein extracts from c-Jun/ and c-Jun/ mouse embryonic fibroblasts
(MEFs) andLu1205 cellswere incubatedwith abiotinylatedoligobearing thebox3 sequence. Complexeswere
pulled down with streptavidin and blotted with the indicated antibodies. G, Ets-1 is involved regulation of
PDK1 expression. Protein extracts obtained from Lu1205 cells transfected with scramble (sc) or Ets-1 siRNA
were analyzed by Western blot using the indicated antibodies. H, c-Jun regulates Ets-1 expression. Protein
extracts from Lu1205 transduced with c-Jun lentiviral shRNA were analyzed by Western blot using the indi-
cated antibodies. PCNA, proliferating cell nuclear antigen.
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autophosphorylation capacity, we assessed the effect of c-Jun
on PDK1 targets Akt and PKC. It is important to note that these
experiments were performed in the absence of any stimuli to
activate c-Jun, Akt, or PKC because these proteins are consti-
tutively activated in melanoma cell lines (4). Consistent with
previous findings (31, 32) inhibition of PDK1 expression by
corresponding siRNA in Lu1205 melanoma cells, which har-
bors mutant PTEN (phosphatase and tensin homolog deleted
on chromosomeTen) and exhibit constitutive phosphorylation
ofAkt, reduced the level of Akt phosphorylation on bothThr308
and Ser473 sites (Fig. 4A). As expected, PDK1 knockdown
affected phosphorylation on Thr308, the site directly phosphor-
ylated by PDK1 on Akt, to a greater extent than Ser473 phos-
phorylation. Given the role of PDK1 in Akt activation and the
finding that PDK1 is regulated by c-Jun, we determined
whether changes in c-Jun expression alter Akt activity. Expres-
sion of TAM67 reduced PDK1 expression and Akt phosphory-
lation on both Thr308 and Ser473 in melanoma cell lines Lu1205
(Fig. 4B) and A375 (supplemental Fig. S10). Reduction of PDK1
levels by TAM67 expression also decreased the degree of phos-
phorylation of S6K1, RSK2 (Fig. 4B), and PKC (see below), indi-
cating thatmultiple PDK1 targets are affected by c-Jun. Expres-
sion of either WT PDK1 or PDK1-A280V (a constitutively
active form of PDK1 (33)) in TAM67-expressing cells restored
Akt phosphorylation to levels observed in Lu1205 control cells
(Fig. 4C). Of note, expression of either WT PDK1 or PDK1-
A280V increased phosphorylation of Thr308 in Lu1205 control
cells (Fig. 4D). Furthermore, phosphorylation levels of Akt sub-
strates PRAS40 and GSK3 were decreased by TAM67 and effi-
ciently rescued by PDK1 expression (Fig. 4E). Consistent with
these observations, Akt activity, assessed by an in vitro kinase
assay, was also reduced by TAM67 and rescued by PDK1 (Fig.
4F). These results suggest that by controlling PDK1 transcrip-
tion, c-Jun contributes to the degree of Akt phosphorylation
and activation. Given that PTENmutation in Lu1205 cells pro-
motes maximal translocation of Akt to the membrane, regula-
tion of PDK1 transcription by c-Jun constitutes a PTEN-inde-
pendent regulation of Akt activity.
c-JunModulates PKC and JNK Activities via PDK1—In addi-
tion to Akt, PDK1 also phosphorylates PKC kinases. Shortly
after its translation and as part of its maturation, PKC is phos-
phorylated by PDK1 in the activation loop, which is important
for its stabilization and subsequent autophosphorylation at res-
idues Thr638 and Ser660 (21). Deficient phosphorylation within
the activation loop results in PKC degradation (34). To deter-
minewhether c-Jun regulation of PDK1 transcription indirectly
regulates PKC levels and phosphorylation, we assessed P-PKC
and total PKC levels in melanoma cells expressing TAM67.
Inhibition of c-Jun function either via TAM67 expression or
c-Jun knockdown reduced bothPDK1 andPKC levels, the latter
detected by a pan-PKC antibody (Fig. 5, A and B). Also, the
prominent protein band detected by the pan-PKC antibody
migrated faster in melanoma cells expressing TAM67, suggest-
ing PKC dephosphorylation (Fig. 5A, and data not shown).
Among the 9 PKC isoforms tested, the expression levels of , ,
, , and  were reduced following inhibition of PDK1 expres-
sion (Fig. 5C). These data are in agreement with the notion that
PDK1 regulates phosphorylation and stability of select PKC iso-
forms (12, 21).
We recently showed that PKC-dependent phosphorylation
enhances JNK activation in concert with activity of upstream
MAPKK (17, 20). Data presented here imply that by regulating
transcription of PDK1 and, subsequently, PKC levels and activ-
ity, c-Jun might also affect PKC-dependent JNK activation.
Consistent with this possibility, reduced PDK1 levels by corre-
sponding siRNA resulted in decreased PKC, P-JNK, and P-c-
Jun levels (Fig. 5D). Altogether, these data establish that c-Jun
regulation of PDK1 expression also contributes to PKC activity
with a concomitant effect on JNK activity.
The possibility that PTEN-Akt can also affect JNK signaling
was recently demonstrated in epidermoid carcinomaA431 cells
and Pten/ MEFs (35). Given that PTEN regulates inositol
1,4,5-trisphosphate cellular levels that are critical for PDK1
phosphorylation of Akt, we used a constitutively active Akt
myristoylated Akt (myr-Akt) to assess whether JNK regulation
by PTEN is mediated by Akt. As shown (Fig. 5E), myr-Akt
expression did not increase levels of P-JNK in A375 or MeWo
cells, which express mutant or WT PTEN, respectively. Treat-
ment of these melanoma cells with the phosphatidylinositol
3-kinase inhibitor LY294002 inhibited Akt phosphorylation
but did not alter levels of P-JNK (Fig. 5F). These observations
suggest that, in melanoma, the PTEN-Akt axis does not consti-
tute a major pathway regulating JNK activity.
c-Jun-dependent PDK1 Expression Contributes to Melanoma
Growth Rate and Tumorigenesis—Because PDK1 controls
AGC family kinases, including Akt, PKC, S6K, and RSK, c-Jun-
dependent changes in PDK1 expression and activity are likely to
affect numerous processes.
Through its ability to influence cell growth and survival via
numerous pathways, c-Jun also promotes tumor development
FIGURE 4. c-Jun regulates Akt activity via PDK1. A, PDK1 is required for Akt phosphorylation and activation. Protein extracts (40 g) from Lu1205 cells
transfected with scrambled (sc) oligonucleotides or siRNA specific for PDK1 were analyzed byWestern blots using the indicated antibodies. B, TAM67 inhibits
constitutive phosphorylation of Akt, S6K1, and RSK2. Protein extracts from Lu1205 or Lu1205 cells stably transfected with FLAG-TAM67were blotted with the
indicated antibodies.C, c-Jun-dependent regulationofAkt activation ismediatedbyPDK1. Lu1205-FLAG-TAM67 cellswere infectedwith retrovirus expressing
either WT PDK1 or the constitutively active PDK1 mutant A280V, and stable lines expressing exogenous PDK1 were established. Both PDK1 proteins are
Myc-tagged. Protein extracts (40 g) were blotted with the indicated antibodies. The intensity of bands corresponding to Thr308 and Ser473 phosphorylation
from three independent experiments was determined, normalized to levels of total Akt, and plotted. Results are shown as themean S.D. **, represents p
0.0005. *, represents p 0.05. D, expression of exogenous PDK1 causes a minimal increase in Akt phosphorylation. Lu1205 cells, which harbor mutant Pten,
were infectedwith retrovirus expressing eitherWTPDK1or the constitutively activemutantA280V, and stable cell lineswere established. Protein extractswere
analyzed as indicated in panel C. * represents p 0.05. E, c-Jun-dependent regulation of PDK1 affects phosphorylation of Akt substrates. Protein extracts from
cells described in panel C were analyzed with the indicated antibodies. The intensity of bands corresponding to p-GSK3 (S9) and p-PRAS40 (T246) was
determined and normalized to total GSK3 and PRAS40, respectively. The degree of phosphorylation in the first lanewas set to 1. Similar results were obtained
in three separate experiments. F, c-Jun-dependent regulation of PDK1 affects Akt kinase activity. Akt was immunoprecipitated from cells described in the
legend for Fig. 3C, and an in vitro kinase assaywas performed. The relative intensity of the phosphorylated substrate is indicated. Similar results were obtained
in three separate experiments.
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and progression (1). Because our
data identified PDK1 as a c-Jun tar-
get, we next addressed whether
PDK1 mediates effects of c-Jun on
cell growth and tumorigenesis.
Consistent with c-Jun oncogenic
activity, TAM67 expression effi-
ciently inhibited cell growth of
Lu1205 melanoma cells (Fig. 6A).
Significantly, transfection of PDK1-
A280V into Lu1205 cells expressing
TAM67 partially restored the
growth rate (Fig. 6A), indicating
that PDK1mediates, at least in part,
the effect of c-Jun on cell growth. To
assess whether changes in growth
rate would affect tumorigenesis,
WT, TAM67, and TAM67 
PDK1-A280V cultures were assayed
in a xenograft model. Notably, the
xenograft tumor volume from
Lu1205 cells expressing TAM67
was markedly lower compared with
Lu1205 control cells. Significantly,
reduced tumor volumewas not seen
in tumor cells co-expressing PDK1
and TAM67 (Fig. 6B). Reduced lev-
els of PDK1 and the corresponding
decrease in Akt phosphorylation
were also seen in the tumor samples
(Fig. 6B).
To verify that tumor growth is
affected by c-Jun-dependent regula-
tion of PDK1 expression, we
repeated the xenograft assay using
melanoma cells that were trans-
duced with c-Jun shRNA. The mel-
anoma cells that were inhibited for
c-Jun expressionwere reconstituted
with wild type or the constitutively
active form of PDK1 (A280V) (Fig.
6,C andD). In linewith the previous
finding, tumor growth of c-Jun
knockdown cells was greatly
reduced. Significantly, the inhibi-
tion of tumor growth upon knock-
down of c-Jun was markedly atten-
uated upon expression of active
PDK1 (Fig. 6, E and F). Taken
together, these findings provide
direct evidence that PDK1 is
required for c-Jun oncogenic
capacity.
Given the link between c-Jun and
PDK1 expression and the observa-
tion of increased c-Jun levels in
human melanomas, we asked
whether PDK1 levels were up-regu-
FIGURE 5. c-Jun modulates PKC and JNK via PDK1 in melanoma. A, TAM67 inhibits PKC protein levels.
Protein extracts (40g) from Lu1205 cells stably transfected with FLAG-TAM67 and control cells were blotted
with pan-p-PKC (Ser660) and pan-PKC antibodies. B, PKC levels are reduced in c-Jun/ fibroblasts. Protein
extracts (40 g) from c-Jun/ and control fibroblasts were blotted with pan-p-PKC (Ser660) and pan-PKC
antibodies. C, PDK1 regulates protein levels of select PKC isoforms. Protein extracts (40 g) from Lu1205 cells
transfected with scrambled (sc) oligonucleotides or a PDK1-specific siRNA were analyzed by Western blots
using antibodies specific for the indicated PKC isoforms.D, PDK1 siRNA inhibits JNK and c-Jun activity. Protein
extracts (40 g) from cells described in C were analyzed by Western blots using the indicated antibodies.
E, inhibition of the phosphatidylinositol 3-kinase/Akt pathway does not affect p-JNK levels. WM9 and Lu1205
cells were treated with 10 M LY294002 for 60 min. Protein samples were analyzed by Western blots with the
indicated antibodies. F, active Akt does not increase p-JNK levels in melanoma. A375 and MeWo cells were
stably transfected with empty vector (V) or pBabe expressing myr-Akt (m-Akt). Protein extracts were blotted
with the indicated antibodies.
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lated in melanoma. Compared with normal melanocytes, most
melanoma cell lines exhibit elevated PDK1 levels (Fig. 7A).
Increased levels of PDK1 coincide with elevated expression of
c-Jun (5 of 7 cell lines: MeWo, WM9, WM115, WM793, and
Lu1205; Fig. 7A). However, as expected, increased PDK1 levels
do not suffice to phosphorylate Akt in WT PTEN cells (Mewo,
Femx, andWM35) because Akt translocation to themembrane
is not expected to take place in these cells. Furthermore, and
significantly, analysis of melanoma tumor samples revealed
that those that harbor increased c-Jun expression also exhibit
elevated PDK1 levels (5 of 5 samples; Fig. 7B). Correlation
between elevated c-Jun, PDK1, and Akt phosphorylation was
3
4
3
FIGURE6. c-Jun-dependentPDK1regulationcontributes tomelanomagrowthand tumorigenesis.A, c-Jun-dependentPDK1expression regulates in vitro
cell growth. Cells (104) described in the legend for Fig. 4Cwereplated and the cell number determinedon the indicateddays. Results are shownasmean S.D.
(n	 3). ** represents p 0.0001. * represents p 0.001. B, c-Jun-dependent PDK1 expression regulates tumor growth in vivo. Cells described in the legend for
Fig. 4Cwere injected subcutaneously intomice and tumor volumewasmeasured at the indicated times. Results are shown asmean S.D. (n	 5). * represents
p  0.0005. Protein extracts (40 g) obtained from tumors removed from mice were analyzed by Western blots using the indicated antibodies. #1 and #2
indicate samples from different mice. C and D, lentiviral c-Jun-specific shRNA efficiently knockdowns c-Jun expression and reduces PDK1 expression. Protein
extracts (30g) from cells transduced with c-Jun-specific shRNAwere analyzed byWestern blotting using the indicated antibodies. E and F, PDK1 expression
reverts the defect in tumor growth of c-Jun knockdown cells. Cells described in D were injected subcutaneously into mice. Tumor growth was measured as
described in B. Results are shown as mean S.D. (n	 4). * represents p 0.0001. F, protein extracts (40 g) obtained from tumors removed frommice were
analyzed by Western blots using the indicated antibodies. #1 and #2 indicate samples from different mice.
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seen in over 50% of these cases, further substantiating the link
established between c-Jun and PDK1, whereas suggesting that
additional regulatory components contribute to Akt activation
in these tumors.
DISCUSSION
Rewired signaling is one mechanism by which tumors over-
come barriers that block uncontrolled proliferation, motility,
and cell death programs in non-transformed cells. Recently we
demonstrated how such re-wiring impacts the c-Jun/JNK path-
way. Constitutive ERK activation increases transcription and
the stability of c-Jun, with consequent effects on the JNK sig-
naling cascade. The present study shows that the signal con-
veyed by ERK and JNK is transmitted by c-Jun to PDK1, a mas-
ter kinase that regulates activation of multiple signaling
pathways such as Akt, PKC, S6K, and RSK.
c-Jun, which is frequently up-regulated in melanoma,
increases PDK1 transcription, leading to elevated PDK1 levels
seen in both cell lines and tumor specimens. Given that PDK1 is
self-activated (trans-autophosphorylation), positive regulation
of PDK1 levels by c-Jun increases the amount of active PDK1
available to phosphorylate its targets.
Of importance is to note that whereas c-Jun activation of
PDK1 is seen in both non-transformed and transformed cells,
PDK1 activation of downstream targets, as shown for Akt,
seems to differ between normal and cancer cells. Consistent
with our findings in melanoma cells, Flynn et al. (31) and Feld-
mann et al. (32) showed that inhibiting PDK1 results in inhibi-
tion of Akt phosphorylation in glioblastoma and prostate can-
cer cells, respectively, suggesting that PDK1 levels or activity
can be a limiting factor for Akt activation. Furthermore, recent
studies have demonstrated the importance of PDK1 signaling
in breast cancer, where increased PDK1 expression has been
associated, in part, with increased copy number for the PDK1
gene (36). Moreover, the PDK1 contribution to human breast
tumor development was also shown to be Akt-independent
(37). Thus, mounting evidence suggest that in human cancer
PDK1 up-regulation can be mediated by multiple pathways,
including Jun-dependent transcription (this study), and
increased PDK1 gene copy number (36), resulting in activation
of downstream pathways, which include Akt, PKC (this study),
and SGK3 (37).
Of note, Akt activity was not reduced in mice expressing a
low level of PDK1 due to hypomorphic mutation (38). This
difference may also be related to the activation of additional
signaling pathways by treatment with growth factors used to
activate Akt in normal cells (38). Such activation is not required
in tumors cells such as themelanoma studied here, because Akt
is already activated (this article and see Refs. 31 and 32). Among
the possible factors thatmay explain the different requirements
of PDK1 for Akt activation in tumor cells are priming phos-
phorylation by other activated protein kinases, including Src
(39), or other post-translational modifications.
Herewedemonstrate that c-Jun-dependent PDK1 regulation
has a direct and a major impact on Akt and PKC activation in
melanoma. Elevated c-Jun and PDK1 levels result in greaterAkt
activity and phosphorylation of Thr308 and, to a lesser extent,
Ser473, possibly due to additional regulatory components
involved in regulation of Ser473 phosphorylation. The up-regu-
lation of c-Jun also result in PDK1-dependent phosphorylation
and stabilization of PKC. This, together with c-Jun-dependent
regulation of the receptor of the PKC, RACK1 (4), provide a
mechanistic explanation for the reported up-regulation of PKC
in melanoma (40).
Because c-Jun was identified as an oncogene, extensive
efforts have been devoted to understanding the mechanisms
underlying that activity. The present study links for the first
time c-Jun with activation of two major signal transduction
pathways, Akt and PKC, whose role in tumor development
and progression is well established in multiple tumor types
including melanoma (reviewed by Lopez Bergami et al. (40)).
We show that the underlying mechanism for such activation
is c-Jun control of PDK1 transcription. The up-regulation of
c-Jun in melanoma increases PDK1 transcription in concert
with transcription factors Sp1 and Ets-1. Accordingly, inhib-
iting c-Jun is expected to have major effects on melanoma
development and progression. Indeed, expression of TAM67
and knockdown of c-Jun in melanoma cells elicited PDK1-
dependent inhibition of cell growth in vitro and reduced in
vivo tumor formation. In identifying a role for c-Jun in reg-
ulating Akt and PKC signaling, our findings provide impor-
tant insight into the mechanism underlying c-Jun oncogenic
activity.
FIGURE 7. A, c-Jun and PDK1 levels increase in melanoma cell lines. Protein
extracts (40 g) from melanoma cell lines were analyzed by Western blots
using the indicated antibodies. Human melanocytes served as controls. The
cell linesWM115,WM793, and Lu1205 have deregulated PTEN. B, PDK1 levels
are increased in melanoma tumor specimens and correlate with c-Jun levels.
Protein samples (80 g) obtained frommelanoma tumors were analyzed by
Western blot using the indicated antibodies.
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